Liposome-coated lipoplex–based carrier for antisense oligonucleotides

References

• Nienhuis AW. Development of gene therapy for blood disorders. Blood 2008; 111:4431-44; PMID:18441245; http://dx.doi.org/10.1182/blood-2007-11-078121
   PubMed Web of Science ®Google Scholar
• Tagami T, Suzuki T, Matsunaga M, Nakamura K, Moriyoshi N, Ishida T, Kiwada H. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int J Pharm 2012; 422:280-9; PMID:22101286; http://dx.doi.org/10.1016/j.ijpharm.2011.10.059
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Kitahara T, Kawakami S, Higuchi Y, Yamaguchi A, Nakagawa H, Kodama Y, Hamamoto T, Hashida M, Sasaki H. Gamma-polyglutamic acid-coated vectors for effective and safe gene therapy. J Control Release 2010; 142:404-10; PMID:19931327; http://dx.doi.org/10.1016/j.jconrel.2009.11.010
   PubMed Web of Science ®Google Scholar
• Zhao X, Pan F, Holt CM, Lewis AL, Lu JR. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert Opin Drug Deliv 2009; 6:673-86; PMID:19552611; http://dx.doi.org/10.1517/17425240902992894
   PubMed Web of Science ®Google Scholar
• Wyrozumska P, Stebelska K, Grzybek M, Sikorski AF. Synthetic Vectors for the genetic drug delivery. In: Mozafari MR, ed. Nanocarriers Technologies: Frontiers of Nanotheraphy. Dordrecht, The Netherlands: Springer 2006:139-74.
   Google Scholar
• Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009; 61:850-62; PMID:19422869; http://dx.doi.org/10.1016/j.addr.2009.04.018
   PubMed Web of Science ®Google Scholar
• Grijalvo S, Avino A, Eritja R. Oligonucleotide delivery: a patent review (2010–2013). Expert Opin Ther Pat 2014; 24:801-19; PMID:24798406; http://dx.doi.org/10.1517/13543776.2014.915944
   PubMed Web of Science ®Google Scholar
• Chang RS, Suh MS, Kim S, Shim G, Lee S, Han SS, Lee KE, Jeon H, Choi HG, Choi Y, et al. Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. Biomaterials 2011; 32:9785-95; PMID:21937102; http://dx.doi.org/10.1016/j.biomaterials.2011.09.017
   PubMed Web of Science ®Google Scholar
• Hoekstra D, Rejman J, Wasungu L, Shi F, Zuhorn I. Gene delivery by cationic lipids: in and out of an endosome. Biochem Soc Trans 2007; 35:68-71; PMID:17233603; http://dx.doi.org/10.1042/BST0350068
   PubMed Web of Science ®Google Scholar
• Stuart DD, Allen TM. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim Biophys Acta 2000; 1463:219-29; PMID:10675501; http://dx.doi.org/10.1016/S0005-2736(99)00209-6
   PubMed Web of Science ®Google Scholar
• Bartsch M, Weeke-Klimp AH, Hoenselaar EP, Stuart MC, Meijer DK, Scherphof GL, Kamps JA. Stabilized lipid coated lipoplexes for the delivery of antisense oligonucleotides to liver endothelial cells in vitro and in vivo. J Drug Target 2004; 12:613-21; PMID:15621687; http://dx.doi.org/10.1080/10611860400013519
   PubMed Web of Science ®Google Scholar
• Stuart DD, Semple SC, Allen TM. High efficiency entrapment of antisense oligonucleotides in liposomes. Methods Enzymol 2004; 387:171-88; PMID:15172164; http://dx.doi.org/10.1016/S0076-6879(04)87011-3
   PubMed Web of Science ®Google Scholar
• Shen JZ, Zhang YY, Fu HY, Wu DS, Zhou HR. Overexpression of microRNA-143 inhibits growth and induces apoptosis in human leukemia cells. Oncol Rep 2014; 31:2035-42; PMID:24626955
   PubMed Web of Science ®Google Scholar
• Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9:47-59; PMID:18097445; http://dx.doi.org/10.1038/nrm2308
   PubMed Web of Science ®Google Scholar
• Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31 Pt 2:2349-70; PMID:20110045; http://dx.doi.org/10.1016/j.clinthera.2009.11.017
   PubMed Web of Science ®Google Scholar
• Vitagliano O, Addeo R, D'Angelo V, Indolfi C, Indolfi P, Casale F. The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev Hematol 2013; 6:587-97; PMID:24083449; http://dx.doi.org/10.1586/17474086.2013.827415
   PubMed Web of Science ®Google Scholar
• Jurecekova J, Hatok J, Stefanikova A, Dobrota D, Racay P. Targeting of Bcl-2 family proteins for treatment of acute leukaemia. Gen Physiol Biophys 2011; 30 Spec No:S3-S12; PMID:21869449; http://dx.doi.org/10.4149/gpb_2011_SI1_3
   PubMedGoogle Scholar
• Buggins AG, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 2010; 34:837-42; PMID:20359747; http://dx.doi.org/10.1016/j.leukres.2010.03.011
   PubMed Web of Science ®Google Scholar
• Moreira JN, Santos A, Simoes S. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials 2006; 1:217-35; PMID:18473975; http://dx.doi.org/10.2174/157488706778250050
   PubMedGoogle Scholar
• Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 2002; 99:3461-4; PMID:11964319; http://dx.doi.org/10.1182/blood.V99.9.3461
   PubMed Web of Science ®Google Scholar
• Rong YP, Aromolaran AS, Bultynck G, Zhong F, Li X, McColl K, Matsuyama S, Herlitze S, Roderick HL, Bootman MD, et al. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. Mol Cell 2008; 31:255-65; PMID:18657507; http://dx.doi.org/10.1016/j.molcel.2008.06.014
   PubMed Web of Science ®Google Scholar
• Fulda S. Inhibitor of apoptosis proteins in pediatric leukemia: molecular pathways and novel approaches to therapy. Front Oncol 2014; 4:3; PMID:24478984; http://dx.doi.org/10.3389/fonc.2014.00003
   PubMedGoogle Scholar
• Dubielecka PM, Jazwiec B, Potoczek S, Wrobel T, Miloszewska J, Haus O, Kuliczkowski K, Sikorski AF. Changes in spectrin organisation in leukaemic and lymphoid cells upon chemotherapy. Biochem Pharmacol 2005; 69:73-85; PMID:15588716; http://dx.doi.org/10.1016/j.bcp.2004.08.031
   PubMed Web of Science ®Google Scholar
• Siwak DR, Tari AM, Lopez-Berestein G. Liposomal antisense oligonucleotides for cancer therapy. Methods Enzymol 2004; 387:241-53; PMID:15172168; http://dx.doi.org/10.1016/S0076-6879(04)87015-0
   PubMed Web of Science ®Google Scholar
• Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, George CM, Szeto L, Vokes EE. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002; 13:539-45; PMID:12056703; http://dx.doi.org/10.1093/annonc/mdf124
   PubMed Web of Science ®Google Scholar
• Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 22:1110-7; PMID:15020613; http://dx.doi.org/10.1200/JCO.2004.10.148
   PubMed Web of Science ®Google Scholar
• Dai G, Chan KK, Liu S, Hoyt D, Whitman S, Klisovic M, Shen T, Caligiuri MA, Byrd J, Grever M, et al. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. Clin Cancer Res 2005; 11:2998-3008; PMID:15837754; http://dx.doi.org/10.1158/1078-0432.CCR-04-1505
   PubMed Web of Science ®Google Scholar
• Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 1995; 34:12877-83; PMID:7548044; http://dx.doi.org/10.1021/bi00039a050
   PubMed Web of Science ®Google Scholar
• Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979; 76:4350-4; PMID:388439; http://dx.doi.org/10.1073/pnas.76.9.4350
   PubMed Web of Science ®Google Scholar